Skip to main content
. Author manuscript; available in PMC: 2019 Apr 5.
Published in final edited form as: Bone Marrow Transplant. 2018 Aug 16;54(4):587–594. doi: 10.1038/s41409-018-0302-6

Figure 3.

Figure 3

Progression-free survival measured from the date of ASCT (Day +0) for patients conditioned with either PG-free MEL (Evomela®) or PG-solubilized MEL (Alkeran®).